Annual report pursuant to Section 13 and 15(d)

12. Commitments and Contingencies (Details Narrative)

v2.4.1.9
12. Commitments and Contingencies (Details Narrative) (USD $)
12 Months Ended
Mar. 31, 2015
Mar. 31, 2014
Rent expense $ 446,000us-gaap_LeaseAndRentalExpense $ 413,000us-gaap_LeaseAndRentalExpense
Potential severance 1,130,000us-gaap_SeveranceCosts1  
Aggregated annual salaries 935,000us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent  
Service fees received 41,000us-gaap_OtherSalesRevenueNet  
Innovacyn    
Accounts receivable 3,000us-gaap_AccountsReceivableRelatedParties
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= ocls_InnovacynMember
220,000us-gaap_AccountsReceivableRelatedParties
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= ocls_InnovacynMember
More Pharma    
Accounts receivable   609,000us-gaap_AccountsReceivableRelatedParties
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= ocls_MorePharmaMember
Amortization of transaction fees 63,000us-gaap_AmortizationOfDeferredCharges
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= ocls_MorePharmaMember
63,000us-gaap_AmortizationOfDeferredCharges
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= ocls_MorePharmaMember
Transaction costs 1,499,000us-gaap_DebtIssuanceCosts
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= ocls_MorePharmaMember
1,501,000us-gaap_DebtIssuanceCosts
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= ocls_MorePharmaMember
Vetericyn and Innovacyn    
Revenue earned 1,120,000us-gaap_ContractsRevenue
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= ocls_VetericynAndInnovacynMember
3,100,000us-gaap_ContractsRevenue
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= ocls_VetericynAndInnovacynMember
Laboratorios Sanfer    
Accounts receivable $ 843,000us-gaap_AccountsReceivableRelatedParties
/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis
= ocls_LaboratoriosSanferMember